LXRX

Lexicon Pharmaceuticals, Inc.

1.24 USD

Last updated Dec 11, 10:11 UTC

Yesterday HIGH

$1.3

Yesterday LOW

$1.24

52w HIGH

$3.79

52w LOW

$0.92

EPS

-0.21

PE

-5.90

Next Earnings

Feb 29, 2024

Overview News Insider Transactions Government Trades

Lexicon Pharmaceuticals, Inc. stock is up 22.77% since 30 days ago. The next earnings date is Feb 29, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 23 December’s closed higher than November.

Lexicon Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the. treatment of neuropathic pain.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

The Woodlands, United States Of America

Website

lexpharma.com

Benzinga Newsdesk

Tue Sep 26, 2023

Lexicon To Present Study Results Relating To Sotagliflozin And LX9211 At The 59th Annual Meeting Of The European Association For The Study Of Diabetes

INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failureLX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic painTHE WOODLANDS, Texas, Sept. 26, 2023 (GLOBE
Benzinga Insights

Thu Sep 21, 2023

Stocks That Hit 52-Week Lows On Thursday

During the session on Thursday, 461 stocks hit new 52-week lows.
Benzinga Insights

Tue Sep 19, 2023

Stocks That Hit 52-Week Lows On Tuesday

During Tuesday's session, 275 companies made new 52-week lows.
Lisa Levin

Mon Sep 18, 2023

Canopy Growth, DocGo And Other Big Stocks Moving Lower On Monday

U.S. stocks traded mostly flat on Monday. Here are some big stocks recording losses in today’s session.
Benzinga Insights

Mon Sep 11, 2023

Stocks That Hit 52-Week Lows On Monday

Monday's session saw 175 companies set new 52-week lows.
Benzinga Insights

Thu Sep 7, 2023

Stocks That Hit 52-Week Lows On Thursday

On Thursday, 283 companies set new 52-week lows.
Benzinga Newsdesk

Thu Sep 7, 2023

Lexicon Announces Series Of Presentations Relating To LX9211, Its Investigational Drug For The Treatment Of Diabetic Peripheral Neuropathic Pain
Benzinga Newsdesk

Mon Aug 21, 2023

Lexicon To Present Analyses Of INPEFA Clinical Study Results And Changing Patterns Of Heart Failure Diagnoses At The European Society Of Cardiology Congress 2023
Benzinga Insights

Mon Aug 14, 2023

Stocks That Hit 52-Week Lows On Monday

During Monday's session, 201 stocks hit new 52-week lows.
Benzinga Newsdesk

Tue Aug 8, 2023

Published Analysis Of Sotagliflozin Clinical Data Demonstrates Significant Reductions In The Risk Of Hospital Readmissions For Heart Failure

Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure Risk Reductions of Approximately 50% Demonstrated for Heart Failure Readmissions and for

COATS LONNEL, Director

Thu Nov 16, 2023

LXRX Recent Insider Trades and Stock Chart

90,000 shares bought
COATS LONNEL, Director

Fri Nov 10, 2023

LXRX Recent Insider Trades and Stock Chart

10,000 shares bought